FMP
Xeris Biopharma Holdings, Inc.
XERS
NASDAQ
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
1.73 USD
-0.0286 (-1.65%)
About
ceo
Mr. Paul R. Edick
sector
Healthcare
industry
Biotechnology
website
https://www.xerispharma.com
exchange
NASDAQ
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its pr...
CIK
0001867096
ISIN
US98422E1038
CUSIP
98422E103
Address
180 North LaSalle Street
Phone
844 445 5704
Country
US
Employee
377
IPO Date
Jun 21, 2018
Summary
CIK
0001867096
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
98422E103
ISIN
US98422E1038
Country
US
Price
1.73
Beta
1.1
Volume Avg.
1.91M
Market Cap
243.18M
Shares
-
52-Week
1.46-3.26
DCF
-0.02
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.85
P/B
-
Website
https://www.xerispharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest XERS News
It looks like there's no news available.
